The identification of specific causal genes and the development of animal models of MND offer realistic hope of new treatments
Since Charcot's first description, motor neurone disease (or amyotrophic lateral sclerosis) has remained an enigma.1 Without a clear understanding of the pathogenesis, and with relatively little therapy to offer other than symptomatic and palliative intervention, clinicians have faced the difficult task of effectively managing patients with this relentlessly progressive disease. However, advances in understanding over the past decade have reignited research interest, renewing hope that a curative approach may be forthcoming.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Charcot JM, Joffroy A. Deux cas d'atrophie musculaire progressive avec lésions de la substance grise et des faisceaux antérolatéraux de la moelle épinière. Arch Physiol Norm Pathol 1869; 2: 744-760.
- 2. MacKenzie RA. Motor neurone disease (MND): a personal perspective. Med J Aust 2003; 178: 344-345.<eMJA full text>
- 3. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
- 4. Ringel SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993; 43: 1316-1322.
- 5. Mogyoros I, Kiernan MC, Burke D, Bostock H. Strength-duration properties of sensory and motor axons in amyotrophic lateral sclerosis. Brain 1998; 121: 851-859.
- 6. Kiernan MC, Guglielmi JM, Kaji R, et al. Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain 2002; 125: 664-675.
- 7. World Federation of Neurology Research Group on Neuromuscular Diseases. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994; 124: 96-107.
- 8. Davenport RJ, Swingler RJ, Chancellor AM, Warlow CP. Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry 1996; 60: 147-151.
- 9. Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review). Neurology 1999; 52: 1311-1323.
- 10. Cazzolli PA, Oppenheimer EA. Home mechanical ventilation for amyotrophic lateral sclerosis: nasal compared to tracheostomy-intermittent positive pressure ventilation. J Neurol Sci 1996; 139(Suppl): 123-128.
- 11. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425-1431.
- 12. Tikka TM, Vartiainen NE, Goldsteins G, et al. Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain 2002; 125: 722-731.
Research support from the Motor Neurone Disease Research Institute of Australia is gratefully acknowledged.